Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Posts Investigator In Singapore, But Trims Foreign Office List

This article was originally published in The Tan Sheet

Executive Summary

FDA's Office of International Programs consolidates its China offices to "strategically focus its resources." FDA shifts away from primarily a domestic focus to global as drug criminal organizations spread globally

You may also be interested in...



FDA Mutual Reliance With EU On Inspections Is Slow Going

FDA still does over 40% of its inspections in Europe even as it acknowledges it must spend the money elsewhere.

FDA’s New Criminal Investigations Chief Wants Global Reach

Office of Criminal Investigations Director George Karavetsos talks about the Park Doctrine and off-label enforcement in interview with “The Pink Sheet.”

FDA Field Operations Would Endure Reductions Under Budget

President Obama’s FY 2016 blueprint includes cuts to ‘low-priority’ enforcement, surveillance and other activities in FDA human drugs and biologics programs, but still increases those operations overall.

Related Content

Topics

UsernamePublicRestriction

Register

PS108131

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel